靶向CD47治疗淋巴瘤研究进展  

Research progress on targeting CD47 in treatment of lymphoma

作　　者：何慧珍 郭轶先[1] 孙婉玲[1] HE Huizhen;GUO Yixian;SUN Wanling(Department of Hematology,Xuanwu Hospital,Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院血液科,北京100053

出　　处：《中国药物警戒》2023年第9期1071-1077,共7页Chinese Journal of Pharmacovigilance

基　　金：北京自然科学基金资助项目(Z200022)。

摘　　要：CD47是近年淋巴瘤治疗中的新兴免疫检查点之一,最重要的作用是在多种通路调控下与巨噬细胞SIRP α受体相互作用,从而抑制巨噬细胞的免疫杀伤作用,使肿瘤细胞达到免疫逃逸。CD47阻断分子种类繁多,其中CD47单克隆抗体最先应用于临床,由于其突出的血液系统不良反应/事件,进一步发展了选择性SIRP α抗体、双克隆抗体等新型药物及联合用药。本文主要综述了CD47分子在淋巴瘤治疗的调控通路、生物学机制、不良反应、相关药物等临床研究进展,以期通过CD47阻断剂的创新药物及联合用药,进一步提高CD47阻断剂的临床疗效。CD47 is one of the emerging immune checkpoints in the treatment of lymphoma in recent years.The most important role of CD47 is to interact with the macrophage receptor SIRPαunder the regulation of various pathways,thereby inhibiting the immune attacks of macrophages and enabling tumor cells to achieve immune escape.There are various of CD47 blocking molecules at present,among which CD47 monoclonal antibody is the first to be applied in clinical practice.In order to reduce the prominent adverse reactions of the blood system,new drugs such as selective SIRPαantibody and double clonal antibody and combined therapy have been further developed.This article mainly reviews the clinical research progress on the regulatory mechanism,adverse reactions and related CD47 blockades in the treatment of lymphoma,so as to further improve clinical development through the innovation and combination of CD47 blockers.

关 键 词：CD47 信号调节蛋白α 巨噬细胞 淋巴瘤 免疫治疗 

分 类 号：R994.11[医药卫生—毒理学] R943.4[医药卫生—药学]